Treatment of B Cell Malignancies Using Afucosylated Pro-Apoptotic ANTI-CD19 Antibodies in Combination with Anti CD20 Antibodies or Chemotherapeutics
International - Drug - Development - Biotech
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,634,488 | Treatment of B Cell Malignancies Using Afucosylated Pro-Apoptotic ANTI-CD19 Antibodies in Combination with Anti CD20 Antibodies or Chemotherapeutics In force · High confidence UsedRemaining | International - Drug - Development -Biotech | In force | High confidence |
1 of 1 record shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.